• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts positive results for V-Go wearable insulin delivery device

June 25, 2018 By Sarah Faulkner

ValeritasValeritas (NSDQ:VLRX) shares jumped this morning after the company touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the company’s wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose.

The company presented three posters at this year’s meeting of the American Diabetes Association in Orlando, Florida.

“The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose.  We believe that is significant for diabetes patients, their medical professionals, payors, and Valeritas,” CEO John Timberlake said in prepared remarks.

Valeritas’ 283-patient retrospective study found that patients with Type II diabetes who switched from insulin pens and syringes to the V-Go product had statistically significant reductions in A1c by more than 1% and total daily dose of insulin at three and seven months. The company also noted that the percent of patients at high risk (with an A1c of > 9%) was reduced by 50% after switching to the V-Go device.

“We categorize patients with an A1C above 9.0% as high risk since they are more likely to have long-term complications that impact health care costs. The significant reduction in A1C and the achievement in A1C goals after switching to V-Go in the Enable study has important implications for treating diabetes. By improving glycemic control, our hope is to reduce rates of complications as well as decrease health care cost, which is a priority for all healthcare systems,” lead author and endocrinologist Dr. Ripu Hundal said.

One analysis of 186 patients from the Enable study specifically focused on patients who were poorly controlled with conventional basal-bolus therapy delivered by multiple daily injections.

The analysis found that lowered A1c levels were sustained until seven months and that patients were able to reduce their total insulin daily dose by 30% after switching to V-Go.

Researchers also studied if how long a patient has been diagnosed with diabetes had an impact in reference to switching from insulin pens and syringes to the V-Go device.

“Findings from the Enable study demonstrated that no matter how long a patient had been diagnosed with diabetes, switching to V-Go from insulin delivery via insulin pens and syringes resulted in significantly lower A1C levels,” lead author Dr. Jane Cases said. “We believe this positive data demonstrates that diabetes duration should not be a factor when determining which patient can benefit from using V-Go.”

VLRX shares were trading at $1.90 in mid-morning activity today, up +33.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS